Key result
New protocol evaluates valsartan and fluvastatin as upstream therapies for hypertensive non-permanent AF.
Answers are grounded in this paper and cite their sources.
Protocol establishes RCT of upstream valsartan-fluvastatin in hypertensive non-permanent AF; leaves open effects on arrhythmia burden or outcomes.
Informed consent statement.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2015) studied this question. Valsartan and fluvastatin are being evaluated as upstream therapeutic strategies for hypertensive patients with non-permanent atrial fibrillation in this study protocol.
Synapse has enriched 10 related papers. Consider them for comparative context: